

Table 1.24
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Males								
All Races		White		Black				
	Rate ^b 2013-2017	APC ^c 2008-2017		Rate ^b 2013-2017	APC ^c 2008-2017			
All Sites	480.3	-1.9*	All Sites	485.5	-1.9*			
Prostate	109.8	-4.5*	Prostate	102.3	-5.0*			
Lung and Bronchus	61.7	-2.9*	Lung and Bronchus	62.2	-2.9*			
Colon and Rectum	43.7	-2.4*	Colon and Rectum	43.0	-2.4*			
Urinary Bladder	34.9	-1.6*	Urinary Bladder	38.2	-1.6*			
Melanoma of the Skin	29.3	1.1*	Melanoma of the Skin	34.6	1.2*			
Non-Hodgkin Lymphoma	23.8	-0.8*	Non-Hodgkin Lymphoma	25.0	-0.8*			
Kidney and Renal Pelvis	22.4	0.4	Kidney and Renal Pelvis	23.0	0.4			
Leukemia	18.1	-0.4	Leukemia	19.2	-0.5			
Oral Cavity and Pharynx	17.2	0.6*	Oral Cavity and Pharynx	18.1	0.8*			
Pancreas	14.9	0.5*	Pancreas	15.0	0.6*			
Liver & IBD ^f	13.8	1.1*	Liver & IBD ^f	12.4	1.5*			
Stomach	9.9	-1.3*	Stomach	8.9	-1.4*			
Myeloma	8.8	0.6	Thyroid	8.6	1.4*			
Thyroid	8.1	1.5*	Brain and ONS ^f	8.3	-0.8*			
Brain and ONS ^f	7.5	-0.8*	Myeloma	8.2	0.5			
Asian/Pacific Islander								
	Rate ^b 2013-2017	APC ^c 2008-2017	American Indian/Alaska Native ^d		Hispanic ^e			
	Rate ^b 2013-2017	APC ^c 2008-2017		Rate ^b 2013-2017	APC ^c 2008-2017			
All Sites	304.4	-1.9*	All Sites	321.0	-1.6*	All Sites	370.4	-2.5*
Prostate	56.7	-5.0*	Prostate	54.6	-5.4*	Prostate	92.0	-5.8*
Lung and Bronchus	46.2	-1.9*	Lung and Bronchus	43.5	-2.6*	Colon and Rectum	39.6	-2.5*
Colon and Rectum	37.9	-2.2*	Colon and Rectum	40.4	-2.4*	Lung and Bronchus	35.1	-3.2*
Liver & IBD ^f	19.9	-2.1*	Kidney and Renal Pelvis	22.9	-0.8	Kidney and Renal Pelvis	21.4	0.8
Non-Hodgkin Lymphoma	16.5	-0.5	Liver & IBD ^f	21.6	1.4	Non-Hodgkin Lymphoma	20.9	-0.6
Urinary Bladder	15.7	-0.9*	Urinary Bladder	16.3	0.5	Liver & IBD ^f	20.3	0.1
Stomach	14.1	-2.5*	Pancreas	12.9	2.8	Urinary Bladder	19.3	-1.6*
Kidney and Renal Pelvis	12.5	0.6	Oral Cavity and Pharynx	11.7	-0.3	Leukemia	13.2	-0.7
Oral Cavity and Pharynx	12.1	0.1	Stomach	11.1	-1.8	Stomach	13.1	-2.2*
Pancreas	11.0	0.3	Non-Hodgkin Lymphoma	10.8	-5.2*	Pancreas	12.5	0.0
Leukemia	9.9	-0.3	Leukemia	10.7	1.2	Oral Cavity and Pharynx	10.0	-1.4
Thyroid	7.9	2.8*	Myeloma	6.7	-	Myeloma	8.2	-0.1
Myeloma	5.0	0.1	Esophagus	6.2	-	Thyroid	5.9	3.0*
Brain and ONS ^f	4.5	0.0	Melanoma of the Skin	5.9	-	Brain and ONS ^f	5.9	-0.7
Esophagus	3.7	-0.4	Testis	5.2	1.3	Testis	5.4	2.0*

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^a Top 15 cancer sites selected based on 2013-2017 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

^d Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^e Rates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^f Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.